Ergoteles LLC Gritstone Bio, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $462,972 - $893,950	-188,200 Reduced 76.23%	58,700 $151,000
Q2 2022 Aug 12, 2022	BUY	$1.77 - $4.34 $381,966 - $936,572	215,800 Added 693.89%	246,900 $597,000
Q1 2022 May 13, 2022	BUY	$4.03 - $12.19 $125,333 - $379,109	31,100 New	31,100 $128,000
Q1 2021 May 12, 2021	SELL	$4.07 - $27.11 $72,039 - $479,847	-17,700 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$2.57 - $4.22 $45,489 - $74,694	17,700 New	17,700 $70,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.